Though, theoretically, INF-α should show promising results in HCC, the drug showed partial response only in 6% of the study subjects (two out of 30) and the majority of the patients discontinued the medication due to intolerable side effects [12]. The gene discussed is IFNA17; the disease is hepatocellular carcinoma.